life-sciences-software
(7)
Suresh Balasubramanian Is Rebuilding the CMO’s Playbook at AI Speed
After three decades across code, cybersecurity, fintech and SaaS, Qualio’s marketing chief is testing a sharper idea: in an AI-first company, the CMO must redesign the work itself.
Christian Rockwell Has a Framework for the Messy Middle
After two decades marketing complicated software, Christian Rockwell’s sharpest idea is also his simplest: know where you are before deciding where to go.
Raj Indupuri Spent 30 Years Making Clinical Trial Data Behave
He began when trial records traveled on paper and sometimes by courier. Three technology shifts later, the eClinical Solutions co-founder is still chasing the same stubborn prize: cleaner data, faster decisions, and software people can trust.
Scott Marshall Is Making Clinical Trial Data Behave
The QuartzBio CEO built his career around an unglamorous but expensive problem: a clinical sample can travel farther than the data that explains it. His answer is a connected system designed to catch the gaps before researchers have to play another round of spreadsheet detective.
Chuck Donnelly Put Space-Age Software to Work in the Preclinical Lab
Before Chuck Donnelly built software for preclinical research, he worked on orbiting instruments, Space Shuttle ground control, and radio astronomy. RockStep Solutions turned that systems instinct toward a quieter frontier: making laboratory data usable.
Brandon Rice Is Turning Drug Development’s Paper Trail Into Working Memory
The Weave Bio CEO began with Neanderthal genomes and ended up rebuilding one of drug development’s least glamorous systems. His wager is simple: let software carry the paperwork so experts can carry the judgment.
Sajith Wickramasekara
Sajith (Saji) Wickramasekara is the co-founder and CEO of Benchling, the R&D cloud platform used by more than 200,000 scientists across pharma, biotech, and academia. He took leave from MIT in 2012 to rebuild the software scientists use at the bench, and has stayed in the CEO seat as the company grew to a roughly $6 billion valuation.